British T-cell cancer biotech Achilles Therapeutics guns for $176M IPO

British T-cell cancer biotech Achilles Therapeutics guns for $176M IPO

Source: 
Fierce Biotech
snippet: 

Achilles Therapeutics is looking for a meaty $176 million initial public offering for its next-gen immuno-oncology work.